<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; inclusion</title>
	<atom:link href="http://www.tapanray.in/tag/inclusion/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>The Indian Drug Industry’s Looming Talent Crisis &#8211; A Recent Landscape</title>
		<link>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape</link>
		<comments>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/#comments</comments>
		<pubDate>Thu, 18 Jul 2024 07:41:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[academia]]></category>
		<category><![CDATA[Academic]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[Diversity]]></category>
		<category><![CDATA[great]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[looming]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[re-skilling]]></category>
		<category><![CDATA[resignation]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[talent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[up-skilling]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10869</guid>
		<description><![CDATA[India&#8217;s pharmaceutical industry, a global generics and drug manufacturing powerhouse, is facing a critical talent deficit. The shortage of skilled professionals is impeding innovation, drug development, and the industry&#8217;s overall competitiveness. This challenge, exacerbated by recent industry dynamics, demands immediate &#8230; <a href="http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why D&amp;I Is A Powerful Growth Driver For Pharma Industry</title>
		<link>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-di-is-a-powerful-growth-driver-for-pharma-industry</link>
		<comments>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/#comments</comments>
		<pubDate>Mon, 10 Jun 2019 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[DI]]></category>
		<category><![CDATA[Diversity]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[empathetic]]></category>
		<category><![CDATA[empathy]]></category>
		<category><![CDATA[facets]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[two]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9578</guid>
		<description><![CDATA[‘Diverse India’ now needs an ‘inclusive society’, vowed the Prime Minister of India, after his massive electoral win on May 23, 2019. Many may consider a part of it as rhetoric, notwithstanding, as and when the government policy of Diversity and Inclusion &#8230; <a href="http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Diversity And Inclusion’: A Missing Link For Indian Pharma</title>
		<link>http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=diversity-and-inclusion-a-missing-link-for-indian-pharma</link>
		<comments>http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/#comments</comments>
		<pubDate>Mon, 25 Jun 2018 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[DI]]></category>
		<category><![CDATA[Diversity]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[Missing]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[oriented]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9015</guid>
		<description><![CDATA[Inadequate access to affordable health care to a vast majority of the population has been a favorite topic of debate, since long, globally. This discourse is generally centered around the least developed and the developing world, such as India. However, &#8230; <a href="http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Alzheimer’s Disease: Robs Memory: Steals Dignity: Escapes Treatment</title>
		<link>http://www.tapanray.in/alzheimers-disease-robs-memory-steals-dignity-escapes-treatment/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=alzheimers-disease-robs-memory-steals-dignity-escapes-treatment</link>
		<comments>http://www.tapanray.in/alzheimers-disease-robs-memory-steals-dignity-escapes-treatment/#comments</comments>
		<pubDate>Mon, 11 Aug 2014 00:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AC Immune.]]></category>
		<category><![CDATA[Actavis]]></category>
		<category><![CDATA[AD]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[Aricept]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[beta-amyloid]]></category>
		<category><![CDATA[Cognex]]></category>
		<category><![CDATA[Crenezumab]]></category>
		<category><![CDATA[dementia]]></category>
		<category><![CDATA[Dignity]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Eisai]]></category>
		<category><![CDATA[Evades]]></category>
		<category><![CDATA[Exelon]]></category>
		<category><![CDATA[Gantenerumab]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[Lundbeck]]></category>
		<category><![CDATA[Memory]]></category>
		<category><![CDATA[Namenda]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Razadyne]]></category>
		<category><![CDATA[Robs]]></category>
		<category><![CDATA[Solanezumab]]></category>
		<category><![CDATA[Steals]]></category>
		<category><![CDATA[Sumeet]]></category>
		<category><![CDATA[Tacrine]]></category>
		<category><![CDATA[tau]]></category>
		<category><![CDATA[TauRx Therapeutics]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5735</guid>
		<description><![CDATA[At a well reputed Mumbai Club, quite unexpectedIy, I bumped into Sumeet (name changed). It has indeed been a long while since we met at his home in South Mumbai. He came there with his wife Shilpa (name changed). Sumeet, was &#8230; <a href="http://www.tapanray.in/alzheimers-disease-robs-memory-steals-dignity-escapes-treatment/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/alzheimers-disease-robs-memory-steals-dignity-escapes-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Revised Mashelkar Committee Report recommends inclusion of ‘incremental innovation’ under patentability criteria.</title>
		<link>http://www.tapanray.in/revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria</link>
		<comments>http://www.tapanray.in/revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria/#comments</comments>
		<pubDate>Sun, 26 Apr 2009 09:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[compliant]]></category>
		<category><![CDATA[criteria]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Mashelkar]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommends]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Revised]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[under]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=906</guid>
		<description><![CDATA[In 2006, the Government of India appointed a Technical Expert Group (TEG) chaired by the eminent scientist and the then Director General of the Council of Scientific and Industrial Research (CSIR) Dr. R.A. Mashelkar, with the following terms of reference:1. &#8230; <a href="http://www.tapanray.in/revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
